ER、PR、Her-2在乳腺癌中的表达

Expressions of ER, PR and Her-2 in breast cancer

目的探讨乳腺癌组织中雌激素受体（ER）、孕激素受体（PR）、人类表皮生长因子受体-2（Her-2）的表达与临床特征的关系。方法用免疫组织化学法检测311例乳腺癌组织中ER、PR、Her-2的表达。结果311例乳腺癌组织中Her-2阳性表达明显低于ER和PR，分别为87例（27．97％）、185例（59．49％）和195例（62．70％）。与非浸润性乳腺癌相比，ER、PR在浸润性乳腺癌中的表达明显减少（P〈0．05）。ER的表达随乳腺癌TNM分期增加而减少（P〈0．05），而PR和Her-2的表达与TNM分期兀关（P〉0．05）：与无腋窝淋巴结转移者相比，有腋窝淋巴结转移的乳腺癌组织中ER表达明显减少，Her-2表达明显增加（P〈0．05）。结论ER、PR、Her-2与乳腺癌的临床特征密切相关，其可能参与乳腺癌的生物学行为调控，常规检测ER、PR、Her-2的表达可为乳腺癌治疗提供依据。

Objective To investigate the relationship between expressions of estrogen receptor （ER）, progesterone receptor（PR） and human epidermal growth factor receptor 2 （Her-2） in 311 cases of breast cancer tissue and their clinical feature. Methods The expressions of ER, PR and Her-2 were detected by immunohistoehemistry in 311 cases of breast cancer tissue proved pathologically. Results The positive rate of ER, PR and Her-2 were 59.49 %, 62.70 % and 27.97 % respectively in breast cancer tissues. Compared with non-invasive breast cancer, the expressions of ER and PR significant decreased in invasive breast cancer （P 〈0.05）. The expression of ER decreased to follow the elevation of TNM status of breast cancer （P 〈0.05）. Compared with patients who had not metastasis in axillary lymph node, the expressions of ER significantly decreased and the expressions of Her-2 significantly increased in patients who had metastasis in axillary lymph node （P 〈0.05）. Conclusion These findings indicate that ER, PR and Her-2 are intimate correlation with clinical feature and maybe participate in biological behaviour regulation of breast cancer. The routine detecting of ER, PR and Her-2 may provide the evidence for breast cancer treatment.